CJC-1295 / Ipamorelin Blend: Research Overview

The CJC-1295 w/o DAC and Ipamorelin combination blend is one of the most widely referenced multi-peptide formulations in growth hormone axis research. CJC-1295 w/o DAC is a GHRH analogue that acts on GHRH receptors in the pituitary, while Ipamorelin is a selective ghrelin mimetic that acts through a distinct receptor — the GHSR-1a. When used in combination, these compounds stimulate GH secretion through complementary receptor systems, and preclinical research has suggested their synergistic activity produces greater GH release than either compound alone. The blend has become a standard reference formulation in endocrinology and metabolic research settings.

Mechanism of Action

CJC-1295 w/o DAC binds to pituitary GHRH receptors and activates the adenylate cyclase-cAMP signaling pathway, promoting GH synthesis and release. Ipamorelin simultaneously engages GHSR-1a receptors through a distinct pathway involving phospholipase C and intracellular calcium mobilization. Because these two receptor systems work in parallel rather than redundantly, their combined activation results in a more robust GH secretion response. This dual-receptor stimulation also preserves the natural pulsatile quality of GH release, which is important for maintaining physiological downstream effects on IGF-1 and target tissues.

Key Research Areas

• Synergistic GH Stimulation: Studies have examined whether CJC-1295 and Ipamorelin together produce supra-additive GH release compared to either compound alone, confirming synergy through their complementary receptor pathways.
• IGF-1 Modulation: Combination protocols have been used to study downstream IGF-1 responses, providing data for metabolic and tissue growth research models.
• Body Composition Research: Animal studies have used this blend to examine effects on lean mass, adiposity, and nitrogen retention in controlled metabolic conditions.
• Aging and GH Deficiency Models: Preclinical research has used the combination in aged animals to study restoration of GH pulsatility and associated physiological markers.

Research Applications

This combination blend is primarily used in endocrinology research and metabolic studies. In rodent models, it is administered subcutaneously, often timed to coincide with natural GH pulse windows. Researchers studying the GH/IGF-1 axis, body composition changes, or peptide synergy have adopted this blend as a standard tool. It is also used in comparative studies examining different GH secretagogue combinations for potency, duration, and selectivity profiles.

Storage and Handling

The CJC-1295 / Ipamorelin blend is supplied as a co-lyophilized powder. Store at -20°C, protected from light and humidity. Reconstitute with sterile bacteriostatic water using aseptic technique. After reconstitution, store at 2–8°C and use within 28 days. Avoid freeze-thaw cycling after reconstitution.

Available from Alpha Peptides US

Alpha Peptides US offers the CJC-1295 / Ipamorelin Blend for qualified research applications. Designed for GH axis studies requiring dual-receptor stimulation in a single formulation.

This product is intended for laboratory research purposes only. It is not approved by the FDA and is not intended for human or veterinary use, diagnosis, treatment, or prevention of any condition.